Stereotactic body radiotherapy (SBRT) is noninferior to conventional or moderately fractionated radiotherapy for localized ...

Ascension St. John is doing their part to make the fight against cancer as easy as possible. They were the first in the state ...

Prostate cancer is the second leading cause of cancer death among American men. A recent study, conducted by researchers from ...

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Siemens Healthineers, India’s recent partnership with HealthCare Global Enterprises (HCG), is aimed to revolutionize cancer ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

Clarity Pharmaceuticals Dr Alan Taylor    Catherine Strong Executive Chairman   Investor/Media Relations ataylor@claritypharm.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies ("Theranostics") to target cancer first ...

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of ...